LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Strona główna・Stock List・Editas Medicine Inc

Editas Medicine Inc

Closed

SectorHealthcare

2.44 -3.17

Buy Sell

Overview

Share price change

24h

Current

Min

2.4

Max

2.57

Key metrics
By Trading Economics
Income	28M -25M
Sales	4M 7.5M
Profit margin	-332.984
Employees	246
EBITDA	27M -22M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+58.89% upside

Market Stats
By TradingEconomics
Market Cap	-39M 236M
Previous open	5.61
Previous close	2.44

News Sentiment

By Acuity

50%

165 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.33 / 1.54 Support & Resistance

Editas Medicine Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 gru 2025, 17:39 UTC

Major Market Movers

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15 gru 2025, 23:44 UTC

Market Talk

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15 gru 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

15 gru 2025, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15 gru 2025, 22:19 UTC

Market Talk

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15 gru 2025, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

15 gru 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15 gru 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15 gru 2025, 21:23 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15 gru 2025, 21:23 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15 gru 2025, 21:23 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15 gru 2025, 21:22 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15 gru 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Completes Acquisition Of Moveworks >NOW

15 gru 2025, 21:00 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 gru 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 gru 2025, 20:36 UTC

Market Talk

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15 gru 2025, 20:31 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15 gru 2025, 20:27 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15 gru 2025, 20:15 UTC

Market Talk

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15 gru 2025, 19:22 UTC

Market Talk

Gold and Silver Gain to Start Week -- Market Talk

15 gru 2025, 18:37 UTC

Market Talk

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15 gru 2025, 18:29 UTC

Market Talk

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15 gru 2025, 17:58 UTC

Market Talk

Canada Housing Market In Search Of a Bottom -- Market Talk

15 gru 2025, 17:36 UTC

Market Talk

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15 gru 2025, 17:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 gru 2025, 17:36 UTC

Earnings

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15 gru 2025, 17:30 UTC

Acquisitions, Mergers, Takeovers

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Peer Comparison

Price change

Editas Medicine Inc Forecast

Price Target

By TipRanks

58.89% upside

12 Months Forecast

Average 4.02 USD 58.89%

High 5 USD

Low 3 USD

Based on 8 Wall Street analysts offering 12 month price targets forEditas Medicine Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Editas Medicine Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.33 / 1.54Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

165 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.